GBM diagnosisadult glioblastomaglioblastoma (GBM)standards of caretherapeutic and biomarker development
Figures from the paper
Abstract (AI)
Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically are not observed; patients diagnosed with these tumors generally have a dismal prognosis and poor quality of life as the disease progresses. This review summarizes the clinical presentation of GBM, diagnostic methods, evidentiary basis for the current standards of care, and investigational approaches to treat or manage GBM. Because the track record for developing effective therapies for GBM has been dismal, we also review the challenges to successful therapeutic and biomarker development.
Key Findings
1
Adult glioblastoma is a rare malignancy with among the most challenging treatment profiles in oncology.
2
Despite therapeutic advances, patients with glioblastoma generally experience dismal prognoses and declining quality of life as disease progresses.
3
Successful development of effective therapies and biomarkers for glioblastoma remains difficult, reflecting a persistently poor therapeutic track record.
4
The review summarizes glioblastoma’s clinical presentation, diagnostic methods, evidence supporting current standards of care, and investigational treatment approaches.
Research Object
adult glioblastoma (GBM)
Research Subject
clinical presentation, diagnosis, treatment standards, investigational management approaches, and challenges in therapeutic and biomarker development
Publication Details
Publication Date
2017-06-22
Journal
Publisher
ISSN
Cited by
816
Access Type
Author Information
Download PDF
Subscribe to digest